ELDN vs. KRRO, EFTR, UBX, XLO, RGLS, SLS, GANX, SLGL, CLRB, and RZLT
Should you be buying Eledon Pharmaceuticals stock or one of its competitors? The main competitors of Eledon Pharmaceuticals include Korro Bio (KRRO), eFFECTOR Therapeutics (EFTR), Unity Biotechnology (UBX), Xilio Therapeutics (XLO), Regulus Therapeutics (RGLS), SELLAS Life Sciences Group (SLS), Gain Therapeutics (GANX), Sol-Gel Technologies (SLGL), Cellectar Biosciences (CLRB), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.
Korro Bio (NASDAQ:KRRO) and Eledon Pharmaceuticals (NASDAQ:ELDN) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, community ranking, institutional ownership, earnings, media sentiment and analyst recommendations.
Korro Bio currently has a consensus target price of $125.00, suggesting a potential upside of 211.10%. Eledon Pharmaceuticals has a consensus target price of $10.67, suggesting a potential upside of 852.38%. Given Korro Bio's higher possible upside, analysts plainly believe Eledon Pharmaceuticals is more favorable than Korro Bio.
Korro Bio has higher revenue and earnings than Eledon Pharmaceuticals. Korro Bio is trading at a lower price-to-earnings ratio than Eledon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Korro Bio had 1 more articles in the media than Eledon Pharmaceuticals. MarketBeat recorded 4 mentions for Korro Bio and 3 mentions for Eledon Pharmaceuticals. Eledon Pharmaceuticals' average media sentiment score of 0.64 beat Korro Bio's score of 0.44 indicating that Korro Bio is being referred to more favorably in the media.
13.2% of Korro Bio shares are owned by institutional investors. Comparatively, 39.4% of Eledon Pharmaceuticals shares are owned by institutional investors. 16.8% of Korro Bio shares are owned by company insiders. Comparatively, 19.4% of Eledon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Eledon Pharmaceuticals received 21 more outperform votes than Korro Bio when rated by MarketBeat users. However, 100.00% of users gave Korro Bio an outperform vote while only 69.70% of users gave Eledon Pharmaceuticals an outperform vote.
Korro Bio has a beta of 0.84, meaning that its share price is 16% less volatile than the S&P 500. Comparatively, Eledon Pharmaceuticals has a beta of 1.82, meaning that its share price is 82% more volatile than the S&P 500.
Korro Bio's return on equity of -46.18% beat Eledon Pharmaceuticals' return on equity.
Summary
Eledon Pharmaceuticals beats Korro Bio on 10 of the 15 factors compared between the two stocks.
Get Eledon Pharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELDN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Eledon Pharmaceuticals Competitors List
Related Companies and Tools
